Articles with public access mandates - Guillermo Garcia-ManeroLearn more
Not available anywhere: 43
Review
Myelodysplastic syndromes
PL Greenberg, E Attar, JM Bennett, CD Bloomfield, CM De Castro, ...
Journal of the National Comprehensive Cancer Network 9 (1), 30-56, 2011
Mandates: US National Institutes of Health
Review
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ...
The Lancet Haematology 7 (10), e724-e736, 2020
Mandates: US National Institutes of Health
Review
Oncogenic functions of the transcription factor Nrf2
I Gañán-Gómez, Y Wei, H Yang, MC Boyano-Adánez, G García-Manero
Free Radical Biology and Medicine 65, 750-764, 2013
Mandates: Government of Spain
Review
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 …
G Garcia-Manero, P Fenaux, A Al-Kali, MR Baer, MA Sekeres, GJ Roboz, ...
The lancet oncology 17 (4), 496-508, 2016
Mandates: US National Institutes of Health
Review
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
HM Kantarjian, GJ Roboz, PL Kropf, KWL Yee, CL O'Connell, R Tibes, ...
The Lancet Oncology 18 (10), 1317-1326, 2017
Mandates: US National Institutes of Health
Review
Novel drugs for older patients with acute myeloid leukemia
G Montalban-Bravo, G Garcia-Manero
Leukemia 29 (4), 760-769, 2015
Mandates: US National Institutes of Health
Review
Myeloid/lymphoid neoplasms with FGFR1 rearrangement
P Strati, G Tang, DY Duose, S Mallampati, R Luthra, KP Patel, M Hussaini, ...
Leukemia & Lymphoma 59 (7), 1672-1676, 2018
Mandates: US National Institutes of Health
Review
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia
U Rozovski, M Ohanian, F Ravandi, G Garcia-Manero, S Faderl, S Pierce, ...
Leukemia & lymphoma 56 (5), 1392-1397, 2015
Mandates: US National Institutes of Health
Review
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia
M Alfayez, GC Issa, KP Patel, F Wang, X Wang, NJ Short, JE Cortes, ...
Leukemia 35 (3), 691-700, 2021
Mandates: US National Institutes of Health
Review
Phase II trial of MEK inhibitor binimetinib (MEK162) in RAS-mutant acute myeloid leukemia
A Maiti, K Naqvi, TM Kadia, G Borthakur, K Takahashi, P Bose, NG Daver, ...
Clinical Lymphoma Myeloma and Leukemia 19 (3), 142-148. e1, 2019
Mandates: US National Institutes of Health
Review
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse
P Boddu, J Jorgensen, H Kantarjian, G Borthakur, T Kadia, N Daver, ...
Leukemia 32 (1), 241-244, 2018
Mandates: US National Institutes of Health
Review
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
P Bose, S Verstovsek, JE Cortes, S Tse, Y Gasior, N Jain, EJ Jabbour, ...
Leukemia 34 (9), 2489-2492, 2020
Mandates: US National Institutes of Health
Review
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, CD DiNardo, ...
Leukemia 31 (2), 318-324, 2017
Mandates: US National Institutes of Health
Review
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
K Sasaki, HM Kantarjian, S O’Brien, F Ravandi, M Konopleva, ...
International journal of hematology 109, 545-552, 2019
Mandates: US National Institutes of Health
Review
Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation
B Oran, RE Champlin, F Wang, T Tanaka, RM Saliba, G Al-Atrash, ...
Leukemia 36 (1), 257-262, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Review
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
P Boddu, H Kantarjian, F Ravandi, G Garcia-Manero, G Borthakur, ...
Leukemia & Lymphoma 59 (9), 2238-2241, 2018
Mandates: US National Institutes of Health
Review
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
G Montalban-Bravo, D Hammond, CD DiNardo, M Konopleva, ...
Leukemia 35 (5), 1494-1499, 2021
Mandates: US National Institutes of Health
Review
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
Y Sasaki, HM Kantarjian, NJ Short, F Wang, K Furudate, H Uryu, R Garris, ...
Leukemia 36 (5), 1253-1260, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Review
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience
R Assi, H Kantarjian, M Keating, N Pemmaraju, S Verstovsek, ...
Leukemia & Lymphoma 62 (4), 909-917, 2021
Mandates: US National Institutes of Health
Review
Dietary intake of vegetables, fruits, and meats/beans as potential risk factors of acute myeloid leukemia: a Texas case-control study
Y Yamamura, R Oum, KY Elhor Gbito, G Garcia-Manero, SS Strom
Nutrition and cancer 65 (8), 1132-1140, 2013
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program